Skip to content

    Aether Industri.

    AETHER
    Chemicals·24 Jul 2025
    Management Summary

    Aether Industries reported robust financial performance in Q1 FY26, with significant year-on-year growth across revenue, EBITDA, and PAT. The company secured a major 10-year contract with Milliken, dedicating a new facility (Site 3+) for this partnership. Expansion plans for Site 5 and R&D facilities are on track, with commercialization expected in the coming quarters. Management highlighted strong demand, stable margins, and a shortened negotiation-to-commercialization cycle in the current global environment.

    Highlights

    5

    • Total consolidated revenue stood at ₹2,587 million in Q1 FY26, a 35% increase year-on-year from ₹1,920 million in Q1 FY25.

    • EBITDA increased by 94% year-on-year to ₹781 million in Q1 FY26 from ₹402 million in Q1 FY25, with EBITDA margin at 30% (up from 22%).

    • PAT amounted to ₹470 million in Q1 FY26, a 57% increase year-on-year from ₹299 million in Q1 FY25, with PAT margin at 18% (up from 16%).

    • Demand for products in the large-scale manufacturing vertical grew by 9% year-on-year and 8% quarter-on-quarter.

    • Executed a 10-year contract manufacturing agreement with Milliken Chemical & Textile India Company Private Limited, dedicating new Site 3+ for this strategic product.

    What Changed2

    vs Q2 FY26

    Guidance items10 → 18 (+8)Risks discussed2 → 3 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue2,587 Mn+35%YoY
    2. 02EBITDA781 Mn+94%YoY
    3. 03EBITDA Margin30%
    4. 04PAT470 Mn+57.0%YoY
    5. 05PAT Margin18%

    Segment breakdown

    Business Model Contribution
    51% Large-Scale Manufacturing (LSM)37% Contract/Exclusive Manufacturing (CEM)10% Contract Research and Manufacturing Services (CRAMS)
    Sectoral Split
    46% Pharma & Agro (combined)19% Oil & Gas17% Material Science
    List

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹350 crores

    Debt

    Gross ₹180 crores

    Guidance & targets

    18
    CategoryTargetPriority
    Capacity
    Site 3+ Production Commencement
    Q4 FY26
    		High
    Capacity
    Site 5 Production Blocks Commissioning
    end of Q3 FY26
    		High
    Capacity
    Site 5 Production Block Online Timeline
    6-9 months
    		High
    Capacity Utilization
    Site 5 Optimum Operation
    18 months from commercial production
    		High
    Asset Turn
    Site 5 Asset Turn
    1.75x
    		High
    Asset Turn
    Site 5 Asset Turn on Maturity
    1.5x to 1.75x
    		High
    Capex
    R&D Facilities Expansion
    ₹30-40 crores
    		High
    Insurance Claim
    Fixed Assets Loss Settlement
    Q2 FY26
    		High
    Insurance Claim
    FLOP Claim Settlement
    July '25 or August '25
    		High
    Working Capital
    Working Capital Cycle
    165-170 days
    		High
    Working Capital
    Working Capital Cycle
    150 days
    		Medium
    Revenue
    Electrolyte Additives Revenue
    ₹10-15 crores
    		Medium
    Revenue
    Otsuka Chemicals Contract Revenue
    ₹35-40 crores
    		High
    Revenue
    Site 5 LSM/CEM Revenue Inflow
    Q1 FY27
    		High
    Contract Duration
    Milliken Contract Duration
    10 years
    		High
    Market Size
    Site 5 LSM Products Addressable Market
    ₹1,500 crores
    		Medium
    Contract Finalization
    CEM Contract Negotiation Cycle
    less than 4 to 6 months
    		High
    Commercialization
    CEM Commercialization Timeline
    6 months to 2 years
    		High

    Site 5 First Two Production Blocks Commissioning

    end of Q3 FY26
    CurrentProgressing smoothly
    TargetCommissioned by end of Q3 FY26

    Why it matters

    Successful commissioning of Site 5 is crucial for new large-scale manufacturing products and future revenue growth.

    Site 5, which is based out of Panoli continues to progress smoothly and the target to commission the first two production blocks in Phase 1 continues to be -- by the end of quarter 3 of financial year 2026.

    How to verify

    guidance_and_targets[category='Capacity'][metric='Site 5 Production Blocks Commissioning']

    Risks & concerns

    3
    RiskSeverity

    Geopolitical tensions and tariff uncertainties

    Last quarter was marked by heightened geopolitical tensions and tariff uncertainties. — Management acknowledged

    medium

    Macro volatility or soft economic environment

    Despite macro volatility or soft economic environment, client visits and project discussions are increasing. — Management acknowledged

    medium

    Chinese dumping impacting LSM prices

    Prices for products in the LSM business model vertical remained stable, but are still subdued because of Chinese dumping. — Management acknowledged

    medium

    Q&A highlights

    8

    “Actually, the growth factor for contract manufacturing is the Baker, which has kicked in, which started from the last quarter slowly and then we have capitalized in that, and we have taken we have got a revenue of around INR410 million from them, and that is the driving force. Of course, we are also taking up various other contract manufacturing wherein the Aramco material Converge material has also been sold to a couple of customers, and we are ramping up on that. See, the LSM is also, it's going up as Rohan said in his commentary also, there is a volume growth which we are witnessing since last few quarters. This time also in LSM, there is a volume growth itself. The prices are still subdued because of the Chinese dumping.”

    Clarified the specific drivers for CEM and LSM growth, attributing a significant portion to Baker Hughes and acknowledging volume growth in LSM despite pricing pressure.

    asked by Abhijit Akella

    2 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Financial Performance Highlights

    Aether Industries reported a strong Q1 FY26, with total consolidated revenue growing 35% year-on-year to ₹2,587 million from ₹1,920 million in Q1 FY25. EBITDA saw a significant 94% increase to ₹781 million, with the EBITDA margin expanding to 30% from 22% in the prior year. Net profit (PAT) also grew by 57% year-on-year to ₹470 million, resulting in an 18% PAT margin compared to 16% in Q1 FY25.

    02

    Business Model Contribution and Sectoral Shift

    The company's sales composition in Q1 FY26 showed 51% from large-scale manufacturing (LSM), 37% from Contract/Exclusive Manufacturing (CEM), and 10% from Contract Research and Manufacturing Services (CRAMS). There's an ongoing sectoral shift, with Pharma and Agro combined contributing 46%, while Oil & Gas and Material Science segments are increasing their share to 19% and 17% respectively. This aligns with the company's strategy to diversify revenue streams beyond traditional sectors.

    03

    Capex and Expansion Plans on Track

    Aether Industries plans a capex of ₹350 crores for FY26, allocated across R&D, Site 3++, and Panoli (Site 5). Site 3++, dedicated to the new Milliken contract, is expected to commence production by Q4 FY26. Site 5 in Panoli is progressing smoothly, with the first two production blocks targeted for commissioning by the end of Q3 FY26. The company anticipates achieving an asset turn of 1.75x at maturity for Site 5, which will house new large-scale manufacturing products for pharmaceutical, agrochemical, and material science sectors.

    04

    Strategic New Contracts and R&D Initiatives

    A significant development is the 10-year contract manufacturing agreement with Milliken Chemical & Textile India Company Private Limited, for which Site 3+ will be fully dedicated. This product is a new, globally unique offering in the material science polymer industry. The company is also expanding its R&D facilities with a capex of ₹30-40 crores, increasing labs from 15 to 18 and fume hoods from 65 to 130, to support a growing pipeline of over 50 projects, predominantly non-agro and non-pharma.

    05

    Improved Working Capital Management and Insurance Settlements

    The company successfully reduced its working capital cycle to 190 days in Q1 FY26 from 195 days as of March '25, with inventory days decreasing to 165 from 175. The target is to further reduce the cycle to 165-170 days by the end of FY26 and 150 days in the next 2-3 years. Additionally, Aether expects to receive an insurance settlement of ₹50-60 crores for fixed assets loss by Q2 FY26, and the FLOP claim is anticipated to be settled by July or August '25.

    06

    Global Chemical Industry Trends and India's Opportunity

    Management noted a clear trend of Western companies, particularly in Europe, struggling to manufacture in the current environment, leading to increased inquiries and fast-tracking of projects with Indian partners. Aether believes it is well-positioned to capitalize on this 'golden age' for Indian chemical companies, leveraging its R&D capabilities, world-class infrastructure, and strong client relationships. The negotiation and commercialization timelines for new contracts have significantly shortened, reflecting this urgency.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.